ReviewFrontiers in pharmacology2019
Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer's Disease.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Blood pressure and Alzheimer's disease: A review of meta-analysis.Frontiers in neurology · 2022Pooled it
- Effects of a Reminiscence Therapy Program on Neuropsychiatric Symptoms and Quality of Life in People With Dementia: A Pilot Study Comparing Immersive Virtual Reality and Non-immersive Approaches.Dementia (London, England) · 2026Trial
- Trial
- Article
- Article
- Early Behavioral and Cognitive Changes in Patients With Pathologically Confirmed Alzheimer Disease, Lewy Body Dementia, and Mixed Dementia.Neurology open access · 2026Article
- Depression, anxiety, and mental state in patients with early-stage dementia: comparison of reminiscence therapy and cognitive stimulation therapy.Dementia & neuropsychologia · 2026Article
- Latent Profiles Based on Combined Risk Factors for Cognitive Decline in European Older Adults: A Retrospective Study Based on the SHARE HCAP Project.Neurology international · 2025Article
- Implementation of the Cognitive Daisy (COG-D) for improving care planning and delivery for residents with dementia in care homes: results of a feasibility randomised controlled trial.Pilot and feasibility studies · 2025Article
- Caregiver Assessment of Socioemotional Functioning in People Living With Neurodegenerative Disease (Part 2): Concurrent Validity and Test-Retest Reliability of a New Measure.The Gerontologist · 2025Article
- The Implementation of Infant Anoesis and Adult Autonoesis in the Retrogenesis and Staging System of the Neurocognitive Disorders: A Proposal for a Multidimensional Person-Centered Model.Geriatrics (Basel, Switzerland) · 2025Review
- Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.Pharmaceutics · 2025Review
- Review
- Study protocol: randomized controlled trial of an individualized music intervention for people with dementia in the home care setting.BMC psychiatry · 2024Article
- Use of Quantitative Electroencephalography to Inform Age- and Sex-Related Differences in NMDA Receptor Function Following MK-801 Administration.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Assessing the Stability of Clusters of Neuropsychiatric Symptoms in Alzheimer's Disease and Mild Cognitive Impairment.Current Alzheimer research · 2024Article
- Article
- Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms.Genes · 2023Review
- Detection of Alzheimer's Disease Using Logistic Regression and Clock Drawing Errors.Brain sciences · 2023Article
- Understanding Barriers Along the Patient Journey in Alzheimer's Disease Using Social Media Data.Neurology and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease causes both cognitive and non-cognitive symptoms. There is increasing evidence that the presentation and course of Alzheimer's disease is highly heterogenous. This heterogeneity presents challenges to patients, their families, and clinicians due to the difficulty in prognosticating future symptoms and functional impairment. Behavioral and psychiatric symptoms are emerging as a significant contributor to this clinical heterogeneity. These symptoms have been linked to multiple areas of neurodegeneration, which may suggest that they are representative of network-wide dysfunction in the brain. However, current diagnostic criteria for Alzheimer's disease focus exclusively on the cognitive aspects of disease. Behavioral and psychiatric symptoms have been found in multiple studies to be related to disease severity and to contribute to disease progression over time. A better understanding of how behavioral and psychiatric symptoms relate to cognitive aspects of Alzheimer's disease would help to refine the models of disease and hopefully lead to improved ability to develop therapeutic options for this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.